Why the study?
Do early rhythm control and advanced ablation strategies improve clinical outcomes and reduce disease progression in patients with atrial fibrillation?
Do early rhythm control and advanced ablation strategies improve clinical outcomes and reduce disease progression in patients with atrial fibrillation?
The year 2021 provided landmark evidence supporting early rhythm control and first-line catheter ablation to prevent disease progression and improve hard clinical outcomes in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support early rhythm control in select AF patients; leaves open need for further randomized confirmation.
The EAST-AF4NET trial and early treatment of atrial fibrillationHow we view AF has evolved rapidly over the last several decades, but we have long required a contemporary version of the classical Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) and Rate Control Efficacy in Permanent Atrial Fibrillation (RACE) trials.3,4 Despite the dozens of commentaries and subgroup analyses performed, the resounding message to the medical community was that rate control and oral anticoagulation were equivalent to rhythm control.Obviously, our treatment options for AF have evolved, but until the Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST-AF4NET), 5,6 we still were without data supporting more aggressive treatment for AF rhythm control with implications for the general
No takes yet. Share an insight, caveat, or question.
Sardana et al. (2022) conducted a review in Atrial Fibrillation. Early rhythm control and ablation strategies vs. Rate control and antiarrhythmic drugs was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: